Detalles de la búsqueda
1.
Bimekizumab versus Adalimumab in Plaque Psoriasis.
N Engl J Med
; 385(2): 130-141, 2021 07 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33891379
2.
Bimekizumab versus Secukinumab in Plaque Psoriasis.
N Engl J Med
; 385(2): 142-152, 2021 07 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33891380
3.
The efficacy of the analgesic GlyT2 inhibitor, ORG25543, is determined by two connected allosteric sites.
J Neurochem
; 2023 Dec 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-38131125
4.
Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial.
Lancet
; 397(10273): 475-486, 2021 02 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33549192
5.
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.
Lancet
; 397(10273): 487-498, 2021 02 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33549193
6.
Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study.
J Am Acad Dermatol
; 83(5): 1367-1374, 2020 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-32473974
7.
A non-retinoid antagonist of retinol-binding protein 4 rescues phenotype in a model of Stargardt disease without inhibiting the visual cycle.
J Biol Chem
; 293(29): 11574-11588, 2018 07 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-29871924
8.
Bimekizumab versus Adalimumab in Plaque Psoriasis. Reply.
N Engl J Med
; 385(12): 1150, 2021 09 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-34525294
9.
A novel RPE65 inhibitor CU239 suppresses visual cycle and prevents retinal degeneration.
Biochim Biophys Acta Mol Basis Dis
; 1864(7): 2420-2429, 2018 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-29684583
10.
Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial.
J Am Acad Dermatol
; 79(2): 277-286.e10, 2018 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-29609013
11.
Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study.
Lancet
; 388(10061): 2763-2774, 2016 12 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-27863807
12.
An isothermal calorimetry assay for determining steady state kinetic and enzyme inhibition parameters for SARS-CoV-2 3CL-protease.
bioRxiv
; 2024 Jan 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-38352570
13.
Modulation of NMDA receptor function as a treatment for schizophrenia.
Bioorg Med Chem Lett
; 23(18): 5034-44, 2013 Sep 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-23916256
14.
Design, synthesis, and SAR of N-((1-(4-(propylsulfonyl)piperazin-1-yl)cycloalkyl)methyl)benzamide inhibitors of glycine transporter-1.
Bioorg Med Chem Lett
; 23(5): 1257-61, 2013 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-23380375
15.
Novel Phenylene Lipids That Are Positive Allosteric Modulators of Glycine Receptors and Inhibitors of Glycine Transporter 2.
ACS Chem Neurosci
; 14(15): 2634-2647, 2023 08 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-37466545
16.
Structural similarities between SARS-CoV2 3CLpro and other viral proteases suggest potential lead molecules for developing broad spectrum antivirals.
Front Chem
; 10: 948553, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36353143
17.
The novel visual cycle inhibitor (±)-RPE65-61 protects retinal photoreceptors from light-induced degeneration.
PLoS One
; 17(10): e0269437, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36227868
18.
Novel serotonin type 3 receptor partial agonists for the potential treatment of irritable bowel syndrome.
Bioorg Med Chem Lett
; 21(1): 58-61, 2011 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-21146988
19.
Inhibition of Glycine Re-Uptake: A Potential Approach for Treating Pain by Augmenting Glycine-Mediated Spinal Neurotransmission and Blunting Central Nociceptive Signaling.
Biomolecules
; 11(6)2021 06 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34200954
20.
Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM), a Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Data from the BE VIVID and BE READY Phase 3 Trials.
Dermatol Ther (Heidelb)
; 11(5): 1551-1569, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34260044